vs

Side-by-side financial comparison of American Outdoor Brands, Inc. (AOUT) and GYRE THERAPEUTICS, INC. (GYRE). Click either name above to swap in a different company.

American Outdoor Brands, Inc. is the larger business by last-quarter revenue ($57.2M vs $37.2M, roughly 1.5× GYRE THERAPEUTICS, INC.). American Outdoor Brands, Inc. runs the higher net margin — 3.6% vs -3.7%, a 7.3% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs -5.0%). GYRE THERAPEUTICS, INC. produced more free cash flow last quarter ($-5.8M vs $-14.1M). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs 3.5%).

Deckers Outdoor Corporation, doing business as Deckers Brands, is an American footwear designer and distributor founded in 1973 and based in Goleta, California. The company's portfolio of brands includes UGG, Teva, and Hoka. It was founded by Doug Otto and Karl F. Lopker.

GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.

AOUT vs GYRE — Head-to-Head

Bigger by revenue
AOUT
AOUT
1.5× larger
AOUT
$57.2M
$37.2M
GYRE
Growing faster (revenue YoY)
GYRE
GYRE
+38.5% gap
GYRE
33.4%
-5.0%
AOUT
Higher net margin
AOUT
AOUT
7.3% more per $
AOUT
3.6%
-3.7%
GYRE
More free cash flow
GYRE
GYRE
$8.3M more FCF
GYRE
$-5.8M
$-14.1M
AOUT
Faster 2-yr revenue CAGR
GYRE
GYRE
Annualised
GYRE
17.0%
3.5%
AOUT

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
AOUT
AOUT
GYRE
GYRE
Revenue
$57.2M
$37.2M
Net Profit
$2.1M
$-1.4M
Gross Margin
45.6%
95.3%
Operating Margin
3.7%
0.3%
Net Margin
3.6%
-3.7%
Revenue YoY
-5.0%
33.4%
Net Profit YoY
-33.3%
-340.1%
EPS (diluted)
$0.16
$-0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AOUT
AOUT
GYRE
GYRE
Q4 25
$57.2M
$37.2M
Q3 25
$29.7M
$30.6M
Q2 25
$61.9M
$26.8M
Q1 25
$58.5M
$22.1M
Q4 24
$60.2M
$27.9M
Q3 24
$41.6M
$25.5M
Q2 24
$46.3M
$25.2M
Q1 24
$53.4M
$27.2M
Net Profit
AOUT
AOUT
GYRE
GYRE
Q4 25
$2.1M
$-1.4M
Q3 25
$-6.8M
$5.9M
Q2 25
$-992.0K
$1.6M
Q1 25
$169.0K
$3.7M
Q4 24
$3.1M
$569.0K
Q3 24
$-2.4M
$2.9M
Q2 24
$-5.3M
$4.5M
Q1 24
$-2.9M
$9.9M
Gross Margin
AOUT
AOUT
GYRE
GYRE
Q4 25
45.6%
95.3%
Q3 25
46.7%
94.7%
Q2 25
40.9%
95.7%
Q1 25
44.7%
95.9%
Q4 24
48.0%
95.8%
Q3 24
45.4%
96.2%
Q2 24
41.9%
96.9%
Q1 24
42.7%
96.4%
Operating Margin
AOUT
AOUT
GYRE
GYRE
Q4 25
3.7%
0.3%
Q3 25
-23.0%
22.7%
Q2 25
-1.5%
8.1%
Q1 25
0.5%
10.3%
Q4 24
5.1%
2.4%
Q3 24
-6.2%
16.6%
Q2 24
-11.9%
12.7%
Q1 24
-5.4%
29.7%
Net Margin
AOUT
AOUT
GYRE
GYRE
Q4 25
3.6%
-3.7%
Q3 25
-23.0%
19.4%
Q2 25
-1.6%
5.9%
Q1 25
0.3%
16.9%
Q4 24
5.2%
2.0%
Q3 24
-5.7%
11.2%
Q2 24
-11.5%
18.0%
Q1 24
-5.4%
36.6%
EPS (diluted)
AOUT
AOUT
GYRE
GYRE
Q4 25
$0.16
$-0.01
Q3 25
$-0.54
$0.03
Q2 25
$-0.08
$0.00
Q1 25
$0.01
$0.00
Q4 24
$0.24
$0.00
Q3 24
$-0.18
$0.01
Q2 24
$-0.41
$0.01
Q1 24
$-0.23
$0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AOUT
AOUT
GYRE
GYRE
Cash + ST InvestmentsLiquidity on hand
$3.1M
$52.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$170.4M
$106.0M
Total Assets
$240.9M
$166.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AOUT
AOUT
GYRE
GYRE
Q4 25
$3.1M
$52.4M
Q3 25
$17.8M
$60.0M
Q2 25
$23.4M
$54.4M
Q1 25
$17.1M
$29.9M
Q4 24
$14.2M
$26.7M
Q3 24
$23.5M
$25.1M
Q2 24
$29.7M
$25.1M
Q1 24
$15.9M
$37.4M
Stockholders' Equity
AOUT
AOUT
GYRE
GYRE
Q4 25
$170.4M
$106.0M
Q3 25
$167.8M
$101.9M
Q2 25
$177.6M
$92.0M
Q1 25
$178.7M
$68.1M
Q4 24
$178.9M
$63.3M
Q3 24
$175.7M
$63.2M
Q2 24
$177.9M
$60.4M
Q1 24
$182.4M
$56.6M
Total Assets
AOUT
AOUT
GYRE
GYRE
Q4 25
$240.9M
$166.1M
Q3 25
$241.9M
$159.4M
Q2 25
$246.4M
$152.6M
Q1 25
$245.9M
$129.8M
Q4 24
$254.1M
$125.4M
Q3 24
$244.8M
$125.2M
Q2 24
$240.6M
$120.9M
Q1 24
$239.1M
$122.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AOUT
AOUT
GYRE
GYRE
Operating Cash FlowLast quarter
$-13.3M
$-5.6M
Free Cash FlowOCF − Capex
$-14.1M
$-5.8M
FCF MarginFCF / Revenue
-24.6%
-15.5%
Capex IntensityCapex / Revenue
1.3%
0.4%
Cash ConversionOCF / Net Profit
-6.41×
TTM Free Cash FlowTrailing 4 quarters
$-4.7M
$-180.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AOUT
AOUT
GYRE
GYRE
Q4 25
$-13.3M
$-5.6M
Q3 25
$-1.7M
$4.7M
Q2 25
$7.8M
$2.1M
Q1 25
$5.9M
$-129.0K
Q4 24
$-7.9M
$-2.8M
Q3 24
$-4.4M
$1.7M
Q2 24
$14.7M
$-5.5M
Q1 24
$13.0M
$2.9M
Free Cash Flow
AOUT
AOUT
GYRE
GYRE
Q4 25
$-14.1M
$-5.8M
Q3 25
$-2.0M
$4.0M
Q2 25
$7.2M
$1.8M
Q1 25
$4.2M
$-251.0K
Q4 24
$-8.0M
$-2.8M
Q3 24
$-5.2M
$1.0M
Q2 24
$14.2M
$-6.9M
Q1 24
$9.7M
$2.7M
FCF Margin
AOUT
AOUT
GYRE
GYRE
Q4 25
-24.6%
-15.5%
Q3 25
-6.7%
13.1%
Q2 25
11.6%
6.8%
Q1 25
7.2%
-1.1%
Q4 24
-13.3%
-10.1%
Q3 24
-12.5%
4.1%
Q2 24
30.6%
-27.5%
Q1 24
18.2%
9.8%
Capex Intensity
AOUT
AOUT
GYRE
GYRE
Q4 25
1.3%
0.4%
Q3 25
1.0%
2.2%
Q2 25
0.9%
1.0%
Q1 25
2.9%
0.6%
Q4 24
0.1%
0.2%
Q3 24
2.0%
2.7%
Q2 24
1.1%
5.8%
Q1 24
6.2%
0.9%
Cash Conversion
AOUT
AOUT
GYRE
GYRE
Q4 25
-6.41×
Q3 25
0.79×
Q2 25
1.32×
Q1 25
34.86×
-0.03×
Q4 24
-2.55×
-4.85×
Q3 24
0.60×
Q2 24
-1.21×
Q1 24
0.29×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AOUT
AOUT

Traditional Channels Net Sales$36.8M64%
E Commerce Channels Net Sales$20.4M36%

GYRE
GYRE

Segment breakdown not available.

Related Comparisons